Table 2

Univariate and multivariate analyses for sustained virologic response to the combination therapy with peginterferon and ribavirin in patients who underwent response guided therapy according to the AASLD guidelines
Univariate analysis Multivariate analysis* Odds ratio (95% confidence interval)
Age (years) < 0.001 N.S.
Sex (male/female) 0.005 N.S.
BMI, median (range) N.S.
Prior treatment for HCV (no/yes) N.S.
Pretreatment HCV RNA levels (log10 IU/mL), (≤6.0 vs. 6.0<) 0.015 0.013 2.235 (1.189-4.203)
Platelet count (×103/μL) < 0.001 0.011 1.007 (1.002-1.013)
Hemoglobin (g/dL) 0.002 N.S.
Neutrophil count (/μL) 0.003 N.S.
Alanine aminotransferase (IU/L) N.S.
Total-cholesterol (mg/dL) 0.001 N.S.
γ-glutamyl transpeptidase (IU/L) 0.014 N.S.
Fibrosis score (F1 or F2/F3 or F4) < 0.001 N.S.
Activity score (A1 or A2/A3 or A4) 0.002 N.S.
Genetic polymorphisms of rs8099917 (TT/GG or TG) < 0.001 < 0.001 5.782 (2.298-14.552)
Amino acid at residue 70 of HCV core (arginine/glutamine or histidine) < 0.001 N.S.
Amino acid sequence of ISDR (non-wild-type/wild-type) < 0.001 0.038 2.077 (1.041-4.147)
Reduction of HCV RNA [Pre - 4 week] (log10 IU/mL), (≤2.8 vs. 2.8<) < 0.001 < 0.001 3.911 (1.935-7.908)
Reduction of HCV RNA [Pre - 12 week] (log10 IU/mL), (≤4.9 vs. 4.9<) < 0.001 0.013 2.578 (1.220-5.448)

*Multivariate analysis was performed on 314 patients in whom all variables were available.

(N = 516).

Toyoda et al.

Toyoda et al. BMC Infectious Diseases 2012 12:324   doi:10.1186/1471-2334-12-324

Open Data